189 related articles for article (PubMed ID: 31559512)
21. Alternative monitoring of argatroban using plasma-diluted thrombin time.
Wanat MA; Hart SR; Putney D; Liebl MG; Chandler W
Ann Pharmacother; 2013 Apr; 47(4):e18. PubMed ID: 23482736
[TBL] [Abstract][Full Text] [Related]
22. Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.
Moffett BS; Teruya J
Arch Pathol Lab Med; 2014 Sep; 138(9):1229-32. PubMed ID: 25171706
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of direct thrombin inhibitors during a critical heparin shortage.
Ji CS; Roberts RJ; Barra ME; Lee H; Rosovsky RP
J Thromb Thrombolysis; 2021 Aug; 52(2):662-673. PubMed ID: 33400098
[TBL] [Abstract][Full Text] [Related]
24. Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia.
Duewell BE; Briski MJ; Feih JT; Rinka JRG; Tawil JN
J Pharm Pract; 2021 Aug; 34(4):529-534. PubMed ID: 31645190
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of anticoagulant effects of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Harenberg J
Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
[TBL] [Abstract][Full Text] [Related]
26. Laboratory methods for monitoring argatroban in heparin-induced thrombocytopenia.
Guy S; Kitchen S; Hopkins B; Chunara Z; Stephenson-Brown A; van Veen JJ
Int J Lab Hematol; 2022 Apr; 44(2):399-406. PubMed ID: 34755452
[TBL] [Abstract][Full Text] [Related]
27. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.
Tsu LV; Dager WE
Pharmacotherapy; 2012 Jan; 32(1):20-6. PubMed ID: 22392825
[TBL] [Abstract][Full Text] [Related]
28. Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. Results of an in-vitro study.
Maegdefessel L; Linde T; Michel T; Hamilton K; Steinseifer U; Friedrich I; Schubert S; Hauroeder B; Raaz U; Buerke M; Werdan K; Schlitt A
Thromb Haemost; 2009 Jun; 101(6):1163-9. PubMed ID: 19492162
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia.
Kiser TH; Mann AM; Trujillo TC; Hassell KL
Am J Hematol; 2011 Mar; 86(3):267-72. PubMed ID: 21328434
[TBL] [Abstract][Full Text] [Related]
30. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time.
Love JE; Ferrell C; Chandler WL
Thromb Haemost; 2007 Jul; 98(1):234-42. PubMed ID: 17598018
[TBL] [Abstract][Full Text] [Related]
31. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
Kher A; Gouin I; Samama MM
Ann Biol Clin (Paris); 2000; 58(5):575-9. PubMed ID: 11022100
[TBL] [Abstract][Full Text] [Related]
32. Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
Peetermans M; Liesenborghs L; Peerlinck K; Wijngaerden EV; Gheysens O; Goffin KE; Hoylaerts MF; Jacquemin M; Verhaegen J; Peetermans WE; Verhamme P; Vanassche T;
Thromb Haemost; 2018 May; 118(5):818-829. PubMed ID: 29614521
[TBL] [Abstract][Full Text] [Related]
33. Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors.
Cooper T; White CL; Taber D; Uber WE; Kokko H; Mazur J
Am J Health Syst Pharm; 2012 Nov; 69(22):1993-8. PubMed ID: 23135566
[TBL] [Abstract][Full Text] [Related]
34. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.
Tsu LV; Dager WE
Ann Pharmacother; 2011 Oct; 45(10):1185-92. PubMed ID: 21881032
[TBL] [Abstract][Full Text] [Related]
35. Heparin-Induced Thrombocytopenia in Infants after Heart Surgery.
Abdillah JN; Hu Q; Chen X; Chen X; Zhou W; Luo W; Huang L
Thorac Cardiovasc Surg; 2019 Jan; 67(1):21-27. PubMed ID: 29605959
[TBL] [Abstract][Full Text] [Related]
36. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method.
Fenyvesi T; Jörg I; Harenberg J
Pathophysiol Haemost Thromb; 2002; 32(4):174-9. PubMed ID: 12759518
[TBL] [Abstract][Full Text] [Related]
37. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
38. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia.
Runyan CL; Cabral KP; Riker RR; Redding D; May T; Seder DB; Savic M; Hedlund J; Abramson S; Fraser GL
Pharmacotherapy; 2011 Sep; 31(9):850-6. PubMed ID: 21923585
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients.
Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
Thromb Res; 2008; 123(1):159-65. PubMed ID: 18433842
[TBL] [Abstract][Full Text] [Related]
40. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
